104 related articles for article (PubMed ID: 31693749)
1. Ivermectin use in children below 15 kg: potential benefits for onchocerciasis and scabies elimination programmes.
Colebunders R; Wafula ST; Hotterbeekx A; Siewe-Fodjo JN
Br J Dermatol; 2020 Apr; 182(4):1064. PubMed ID: 31693749
[No Abstract] [Full Text] [Related]
2. Ivermectin mass drug administration for onchocerciasis elimination: can it reduce the prevalence of scabies in Ethiopia?
Amsalu T; Enbiale W; Manaye N; Ayalew A; Workineh A; De Vries H; Van Griensven J
J Infect Dev Ctries; 2022 Aug; 16(8.1):35S-40S. PubMed ID: 36156500
[TBL] [Abstract][Full Text] [Related]
3. Treatment of 18 children with scabies or cutaneous larva migrans using ivermectin.
del Mar Sáez-De-Ocariz M; McKinster CD; Orozco-Covarrubias L; Tamayo-Sánchez L; Ruiz-Maldonado R
Clin Exp Dermatol; 2002 Jun; 27(4):264-7. PubMed ID: 12139665
[TBL] [Abstract][Full Text] [Related]
4. African Program for Onchocerciasis Control 1995-2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases.
Krotneva SP; Coffeng LE; Noma M; Zouré HG; Bakoné L; Amazigo UV; de Vlas SJ; Stolk WA
PLoS Negl Trop Dis; 2015; 9(9):e0004051. PubMed ID: 26401658
[TBL] [Abstract][Full Text] [Related]
5. Topical ivermectin: a new successful treatment for scabies.
Victoria J; Trujillo R
Pediatr Dermatol; 2001; 18(1):63-5. PubMed ID: 11207977
[TBL] [Abstract][Full Text] [Related]
6. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries.
Brooks PA; Grace RF
J Paediatr Child Health; 2002 Aug; 38(4):401-4. PubMed ID: 12174005
[TBL] [Abstract][Full Text] [Related]
7. Current trend in ivermectin usage for scabies.
Santoro AF; Rezac MA; Lee JB
J Drugs Dermatol; 2003 Aug; 2(4):397-401. PubMed ID: 12884462
[TBL] [Abstract][Full Text] [Related]
8. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin.
Lawrence G; Leafasia J; Sheridan J; Hills S; Wate J; Wate C; Montgomery J; Pandeya N; Purdie D
Bull World Health Organ; 2005 Jan; 83(1):34-42. PubMed ID: 15682247
[TBL] [Abstract][Full Text] [Related]
9. Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?
Chandler RE
Am J Trop Med Hyg; 2018 Feb; 98(2):382-388. PubMed ID: 29210346
[TBL] [Abstract][Full Text] [Related]
10. Low ivermectin use among 5- to 6-year-old children: observations from door-to-door surveys in onchocerciasis-endemic regions in Africa.
Siewe Fodjo JN; Mubiru F; Ukaga C; Logora MY; Mmbando BP; Mandro M; Njamnshi AK; Colebunders R
Int Health; 2020 Jan; 12(1):72-75. PubMed ID: 31251354
[TBL] [Abstract][Full Text] [Related]
11. [Systemic adverse reactions with ivermectin treatment of scabies].
Sparsa A; Bonnetblanc JM; Peyrot I; Loustaud-Ratti V; Vidal E; Bédane C
Ann Dermatol Venereol; 2006 Oct; 133(10):784-7. PubMed ID: 17072195
[TBL] [Abstract][Full Text] [Related]
12. The impact of ivermectin treatment alone and when in parallel with Simulium neavei elimination on onchocerciasis in Uganda.
Ndyomugyenyi R; Tukesiga E; Büttner DW; Garms R
Trop Med Int Health; 2004 Aug; 9(8):882-6. PubMed ID: 15303993
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin.
Siewe Fodjo JN; Tatah G; Tabah EN; Ngarka L; Nfor LN; Chokote SE; Mengnjo MK; Dema F; Sitouok AT; Nkoro G; Ntone FE; Bissek AZ; Chesnais CB; Boussinesq M; Colebunders R; Njamnshi AK
Infect Dis Poverty; 2018 Dec; 7(1):114. PubMed ID: 30501640
[TBL] [Abstract][Full Text] [Related]
14. The disappearance of onchocerciasis from the Itwara focus, western Uganda after elimination of the vector Simulium neavei and 19 years of annual ivermectin treatments.
Lakwo TL; Garms R; Rubaale T; Katabarwa M; Walsh F; Habomugisha P; Oguttu D; Unnasch T; Namanya H; Tukesiga E; Katamanywa J; Bamuhiiga J; Byamukama E; Agunyo S; Richards F
Acta Trop; 2013 Jun; 126(3):218-21. PubMed ID: 23458325
[TBL] [Abstract][Full Text] [Related]
15. [Ivermectin use in tropical medicine].
Dupouy-Camet J; Yera H; Tourte-Schaefer C
Arch Pediatr; 2003 Dec; 10 Suppl 5():545s-549s. PubMed ID: 15022779
[TBL] [Abstract][Full Text] [Related]
16. Important progress towards elimination of onchocerciasis in the West Region of Cameroon.
Kamga GR; Dissak-Delon FN; Nana-Djeunga HC; Biholong BD; Ghogomu SM; Souopgui J; Kamgno J; Robert A
Parasit Vectors; 2017 Aug; 10(1):373. PubMed ID: 28774318
[TBL] [Abstract][Full Text] [Related]
17. The treatment of scabies with ivermectin.
Meinking TL; Taplin D; Hermida JL; Pardo R; Kerdel FA
N Engl J Med; 1995 Jul; 333(1):26-30. PubMed ID: 7776990
[TBL] [Abstract][Full Text] [Related]
18. Impact of ivermectin on illness and disability associated with onchocerciasis.
Tielsch JM; Beeche A
Trop Med Int Health; 2004 Apr; 9(4):A45-56. PubMed ID: 15078278
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of scabies with oral ivermectin in Nigeria.
Nnoruka EN; Agu CE
Trop Doct; 2001 Jan; 31(1):15-8. PubMed ID: 11205591
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of epilepsy and onchocerciasis after more than 20 years of ivermectin treatment in the Imo River Basin in Nigeria.
Siewe JNF; Ukaga CN; Nwazor EO; Nwoke MO; Nwokeji MC; Onuoha BC; Nwanjor SO; Okeke J; Osahor K; Chimechefulam L; Ogomaka AI; Amaechi AA; Ezenwa CI; Ezike MN; Ikpeama C; Nwachukwu O; Eriama-Joseph AI; Nwoke BEB; Colebunders R
Infect Dis Poverty; 2019 Jan; 8(1):8. PubMed ID: 30670093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
